Proteo Inc. / Proteo Biotech AG Signs an Exclusive License- and Collaboration- Agreement with Artes Biotechnology GmbH.KIEL, Germany -- Leading Technology for the Recombinant Production of Elafin Worldwide Secured Proteo Biotech is producing its Elafin with the patent protected yeast strain Hansenula polymorpha on a recombinant basis for a world market. PROTEO has signed an exclusive License- and collaboration agreement with ARTES ARTES Automated Remote Time Entry System Biotechnology. ,,This agreement will enable us to produce Elafin, in a large scale, very economically by using the in-licensed yeast Hansenula Polymorpha as an high performance expression system. The License- and Collaboration Agreement is an important milestone on our way to world markets and a sustainable development of the company", so Walter J. Thomsen, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Proteo. ,,The commercial use of the Hansenula Technology by Proteo is an additional confirmation for the safety and efficiency of our expression system", so Dr. Michael Piontek, CEO of ARTES Biotechnology. Proteo's Elafin is of human origin and is one of the most potent inhibitors of human elastase elastase /elas·tase/ (e-las´tas) see pancreatic elastase. e·las·tase n. An enzyme found especially in pancreatic juice that catalyzes the hydrolysis of elastin. and proteinase proteinase /pro·tein·ase/ (pro´ten-as?) endopeptidase. pro·tein·ase n. A protease that begins the hydrolytic breakdown of proteins usually by splitting them into polypeptide chains. 3, and therefore a compound with high biological activity and with less unforeseeable Un`fore`see´a`ble a. 1. Incapable of being foreseen. Adj. 1. unforeseeable - incapable of being anticipated; "unforeseeable consequences" unpredictable - not capable of being foretold side effects Side effects Effects of a proposed project on other parts of the firm. and insignificant allergenic Allergenic A substance capable of causing an allergic reaction. Mentioned in: Echinococcosis potential compared to most synthetic alternatives. The results of pre-clinical trials, shows great promise in the treatment of tissue and muscle damage. Elafin reduces damage to heart muscles caused by blood supply deficiencies. This indicates its applicability in the treatment of cardiac infarction. According to the results of pre-clinical trials performed, Elafin reduced extremity damage caused by blood supply deficiencies. This indicates its suitability as a special drug to prevent amputations after serious injuries. Elafin had a similar effect on transplanted hearts, indicating its suitability as a drug to prevent rejections following a transplantation. Further application are being tested. Proteo, founded in 2000 specializes in the biological and medical research and development human derived agents with the focus on drug development, approval, marketing and distribution. Proteo has established its own pilot plant and expertise in scale-up of recombinant protein production. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion